A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO®Tablet) -LIVALO effectiveness and safety (LIVES) study-

Japanese Pharmacology and Therapeutics

Volumn 36, Issue 8, 2008, Pages 709-731

  Kurihara, Yuji ^a   Kawakita, Koji ^a   Douzono, Takashi ^a   Nagasaka, Yoshimasa ^a  

^a KOWA COMPANY LTD   (Japan)

Author keywords

Effectiveness; HMG CoA reductase inhibitor; Long term study; Pitavastatin; Post marketing surveillance; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; BISBIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN; PHENYLALANINE DERIVATIVE; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN; SULFONYLUREA; THIAZOLIDINE DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC RHINITIS; ALOPECIA; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; APPETITE; ARTHRALGIA; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATOPY; BACKACHE; BILIRUBIN BLOOD LEVEL; BLURRED VISION; BRAIN HEMORRHAGE; BRAIN INFARCTION; CATARACT; CEREBELLUM INFARCTION; CHAPPED LIPS; CHEILITIS; CHOLESTEROL BLOOD LEVEL; CHOLINESTERASE BLOOD LEVEL; CHRONIC URTICARIA; CLINICAL TRIAL; COLD SENSATION; COLD SWEAT; COMORBIDITY; CONGESTIVE HEART FAILURE; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COUGHING; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DEFECATION URGENCY; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPHORIA; DYSPNEA; DYSURIA; ECZEMA; EOSINOPHIL COUNT; EPIGASTRIC DISCOMFORT; EROSIVE GASTRITIS; ERYTHEMA; ERYTHROCYTE COUNT; EYELID EDEMA; FACE DISORDER; FACE EDEMA; FACE SWELLING; FACIAL HYPOESTHESIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GINGIVITIS; GLOSSITIS; GLOSSODYNIA; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GRIP STRENGTH; HANGOVER; HEAD DISCOMFORT; HEAD INJURY; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEMATOCRIT; HEMATURIA; HEMORRHAGIC GASTRITIS; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERKALEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPERURICEMIA; HYPESTHESIA; HYPOKALEMIA; HYPOTHYROIDISM; INCIDENCE; INJECTION SITE EDEMA; INJECTION SITE PAIN; INSOMNIA; INTERSTITIAL LUNG DISEASE; INTERSTITIAL NEPHRITIS; INTESTINE SOUND; INTRAOCULAR FOREIGN BODY; IRON DEFICIENCY ANEMIA; JAUNDICE; JOINT SWELLING; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LIP DISEASE; LISTLESSNESS; LIVER DISEASE; LIVER FUNCTION; LONG TERM CARE; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MOUTH PAIN; MUSCLE FATIGUE; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL STIFFNESS; MYALGIA; MYOPATHY; NAIL DISEASE; NAUSEA; NECK PAIN; NEPHROTIC SYNDROME; NOCTURIA; OBSTRUCTIVE JAUNDICE; ORAL HYPOESTHESIA; ORAL PARESTHESIA; OSTEOARTHRITIS; PARESTHESIA; PERIPHERAL EDEMA; PERNICIOUS ANEMIA; PHOTOPHOBIA; PHOTOSENSITIVITY; POLLAKISURIA; POSITIONAL DIZZINESS; POSTMARKETING SURVEILLANCE; PRIMARY PREVENTION; PROTEIN URINE LEVEL; PROTEINURIA; PRURIGO; PRURITUS; PTOSIS; PURPURA; QT PROLONGATION; REFLUX ESOPHAGITIS; RETINA MACULA DEGENERATION; RHABDOMYOLYSIS; RHINITIS; RHINOPHARYNGITIS; RISK FACTOR; SIDE EFFECT; SKIN ALLERGY; SKIN EXFOLIATION; SKIN PAIN; SLEEP DISORDER; SOMNOLENCE; SORE THROAT; STOMACH DISCOMFORT; STOMACH ULCER; STOMATITIS; SUPRAVENTRICULAR PREMATURE BEAT; SYNCOPE; THIRST; THROMBOCYTE COUNT; TINNITUS; TONGUE DISEASE; TOOTH DISEASE; TOOTH PAIN; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL; TRIGEMINUS NEURALGIA; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; URINE COLOR; VOMITING; WHEEZING; XANTHOPSIA;

EID: 52949154682     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, et al. Pharmacological profile of a novet synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneim-Forsch/Drug Res 1997; 47 (II): 904-9.
2. Morikawa S, Umetani M, Nakagawa S, Yamazaki H, Suganami H, Inoue K, et al. Relative induction of mRNA for HMG-CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000; 7: 138-44.
3. Suzuki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis 1999; 146: 259-70.
4. Nakagawa S, Tanabe S, Tamaki T, Wada Y, Yokoo N, Sato F, et al. Effect of NKA-104, an HMG-CoA reductase inhibitor on lipid metabolism in HepG2 cells. Jpn Pharmacol Ther 2001; 29: 51-7.
5. Fujino H, Yamada I, Kojima J, Hirano M, Matsumoto H, Yoneda M. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human. Xenobio Metabol and Dispos 1999; 14 (6): 415-24.
6. Fujino H, Yamada I, Shimada S, Nagao T, Yoneda M. Metabolic fate of pitavastatin (NKA-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Arzneim-Forsch/Drug Res 2002; 52: 745-53.
7. Yamazaki H, Fujino H, Kanazawa M, Tamaki T, Sato F, Suziki M, et al. Pharmacolical and pharmacokinetic features and clinical effects of pitavastatin (LIVALO® Tablet). Folia Pharmacol Jpn 2004; 123: 349-62.
8. Saito Y, Teramoto T, Yamada N, Itakura H, Hata Y, Nakaya N, et al. Clinical efficacy of NK-104 (pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the dose finding, double blind, three-group comparative study. J Clin Therap Med 2001; 17: 829-55.
9. Saito Y, Teramoto T, Yamada N, Itakura H, Hata Y, Nakaya N, et al. A randomized, double-blind trial comparing the efficacy and safety of NK-104 (pitavastatin) versus pravastatin in patients with primary hypercholesterolemia. J Clin Therap Med 2001; 17: 857-83.
10. Teramoto T, Saito Y, Yamada N, Itakura H, Hata Y, Nakaya N, et al. Clinical safety and efficacy of NK-104 (pitavastatin), a new synthetic HMG-CoA reductase inhibitor, in the long-term treatment of hyperlipidemia-results of a multicenter long-term study. J Clin Therap Med 2001; 17: 885-913.
11. Mabuchi H, Koizumi J, Kajinami K, Miyamoto S, Takegoshi T. Long-term effects of NKA-04 (pitavastatin), a new HMG-CoA reductase inhibitor, in patients with heterozygous familial hypercholesterolemia. J Clin Therap Med 2001; 17: 915-43.
12. Ouchi Y, Saito Y, Ito H, Yamada N. Efficacy and safety of NK-104 (pitavastatin), a new HMG-CoA reductase inhibitor, in the elderly patients with hyperlipidemia. Geriat Med 2001; 39: 849-60.
13. Yamada N, Kawazu S, Utsugi T, Morisaki N, Teramoto T, Ishibashi S, et al. Efficacy of pitavastatin for lipid metabolism in non-insulin-dependent diabetes mellitus. J Clin Therap Med 2001; 17: 945-56.
14. Shibuta T, Kato Y, Kakishita T, Tanaka M, Takimoto M. A 3-month oral toxicity study of (+)-monocalcium his [(3R, 5S, 6E)-7- [2-cyclopropyl-4- (4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoate] (NK-104) in dogs followed by a 7-week recovery test. Pharmacometrics 1998; 56: 73-99.
15. Shibuta T, Kato Y, Amano Y, Kakishita T, Tanaka M, Takimoto M. A 12-month oral toxicity study of (+)-monocalcium bis [(3R, 5S, 6E)-7- [2-cyclopropyl-4- (4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoatel (NK-104) in dogs followed by a 2-month recovery test. Pharmacometrics 1998; 56: 101-130.
16. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14: 45-50.
17. Criteria for Severity Rating of Adverse Reactions to Medicines. Notification No. 80, Safety Section, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare, June 29, 1992.
18. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 568-73.